Table I.
Clinical factor | Number of patients (%) |
---|---|
Gender | |
Male | 19 (76) |
Female | 6 (24) |
Age, years | |
Median ± SD | 66.0±6.5 |
<70 | 18 (72) |
≥70 | 7 (28) |
Indications for chemotherapy | |
Recurrence following surgery | 9 (36) |
Advanced cancer | 16 (64) |
Recurrent or metastatic sites | |
Mediastinal lymph node | 8 (32) |
Pleural dissemination | 6 (24) |
Adrenal gland | 5 (20) |
Brain | 4 (16) |
Bone | 3 (12) |
Liver | 2 (8) |
Other | 2 (8) |
Histology | |
Squamous cell carcinoma | 11 (44) |
Adenocarcinoma | 13 (52) |
Large cell carcinoma | 1 (4) |
EGFR mutation | |
Positive | 5 (20) |
Wild type | 16 (64) |
Unknown | 4 (16) |
ALK rearrangement | |
Positive | 0 (0) |
Negative | 6 (24) |
Unknown | 19 (76) |
Phase of nab-paclitaxel chemotherapy | |
2nd line | 13 (52) |
3rd line | 6 (24) |
4th line | 3 (12) |
5th line | 2 (8) |
6th line or later | 1 (4) |
SD, standard deviation; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; nab, nanoparticle albumin-bound.